HI
Hikal Ltd (HIKAL)
₹218.14
Mkt cap
₹2,787 Cr
P/E ratio
65.70
P/B
2.24
Div yield
0.27%
ROE
2.21%
ROCE
3.50%
EPS (TTM)
₹3.32
Book value
₹97
52W range
146–265
Sector
Healthcare
Price history
Previous close
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad {Maharashtra). The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal's R & D facilities are located in Pune. [1]
NSE HIKALBSE 524735
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−17.64% from high₹218
₹146+49.16% from low₹265
Current
₹218.14
Prev close
₹217.89
Day
+0.11%
Price performance
1D
+0.28%
1W
+2.03%
1M
+10.05%
3M
−1.62%
6M
+48.56%
1Y
−15.91%
YTD
−3.89%
Financials
Revenue, profit & margin
P/E ratio
65.7×
HIKAL is 90% above the sector median of 34.6×
HIKAL65.7×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 388.00 | 434.88 | 447.50 | 514.10 | 406.80 | 452.90 | 447.70 | 552.40 | 380.40 | 318.50 | 494.30 | 519.40 | 402.80 | |
| Expenses | 337.70 | 377.36 | 382.80 | 419.70 | 348.80 | 378.00 | 375.60 | 429.00 | 355.30 | 311.30 | 411.60 | 414.00 | 365.80 | |
| Operating Profit | 50.30 | 57.52 | 64.70 | 94.40 | 58.00 | 74.90 | 72.10 | 123.40 | 25.10 | 7.20 | 82.70 | 105.40 | 37.00 | |
| OPM % | 12.96% | 13.23% | 14.46% | 18.36% | 14.26% | 16.54% | 16.10% | 22.34% | 6.60% | 2.26% | 16.73% | 20.29% | 9.19% | |
| Other Income | 0.90 | 0.99 | 0.10 | 0.50 | 0.50 | 0.40 | 3.60 | 0.50 | 1.00 | 1.90 | -35.20 | -40.50 | 10.70 | |
| Interest | 13.80 | 13.08 | 14.20 | 15.30 | 19.80 | 18.80 | 18.70 | 17.90 | 17.10 | 14.90 | 15.50 | 14.60 | 14.90 | |
| Depreciation | 27.70 | 28.57 | 29.00 | 32.30 | 31.80 | 31.70 | 33.20 | 37.70 | 39.40 | 41.20 | 41.20 | 42.00 | 42.70 | |
| Profit before tax | 9.70 | 16.86 | 21.60 | 47.30 | 6.90 | 24.80 | 23.80 | 68.30 | -30.40 | -47.00 | -9.20 | 8.30 | -9.90 | |
| Tax % | 28.87% | 25.44% | 25.46% | 28.33% | 26.09% | 26.21% | 27.73% | 26.50% | -26.32% | -25.74% | -35.87% | -73.49% | -25.25% | |
| Net Profit | 6.90 | 12.57 | 16.10 | 33.90 | 5.10 | 18.30 | 17.20 | 50.20 | -22.40 | -34.90 | -5.90 | 14.40 | -7.40 | |
| EPS in Rs | 0.56 | 1.02 | 1.31 | 2.75 | 0.41 | 1.48 | 1.39 | 4.07 | -1.82 | -2.83 | -0.48 | 1.17 | -0.60 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +2.58% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 6 Aug '26 |
| Earnings day | +2.58% |
| +1 day | +1.49% |
| +5 days | −1.55% |
| +15 days | −7.77% |
| +30 days | +3.49% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202668.85%Promoter
Promoters68.85%
FIIs0.98%0.46
DIIs7.23%0.03
Public22.92%0.41
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Hikal | ₹226.04 | 65.73 | 2,787 | 0.27% | −7 | +27.23% | 403 | +5.89% | 3.50% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts68
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTSep 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024TranscriptNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Sep - Intimation of Analyst and Investor meet pursuant to regulations 30 of SEBI (LODR) Regulations, 2015Announcement under Regulation 30 (LODR)-Newspaper Publication 1 Sep - Newspaper Publication informing about 38th Annual General Meeting and information on e-Voting.Letter To Members Pursuant To Regulation 36(1)(B) Of SEBI (LODR) Regulations, 2015 31 Aug - Hikal shares AGM notice, annual report web-link, and KYC update reminder for FY2025-26.Business Responsibility and Sustainability Reporting (BRSR) 31 Aug - Hikal filed its FY 2025-26 Business Responsibility and Sustainability Report on August 31, 2026.Reg. 34 (1) Annual Report. 31 Aug